Geron Corporation (Nasdaq: GERN) publishes preclinical data for GRN163L.

GRN163L is a telomerase inhibitor drug.

The data published ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE